LSLance A. Stechschulte

Lance A. Stechschulte

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Lance A. Stechschulte has a total of 62 co-authors. Here are the top co-authors by number of shared publications:

  • Terry D. Hinds

    Drug & Disease Discovery D3 Research Center, Department of Pharmacology and Nutritional Sciences, University of Kentucky College of Medicine, Lexington, KY 40508, USA

    11 shared publications
  • Edwin R. Sanchez

    Department of Physiology and Pharmacology, University of Toledo College of Medicine, Toledo, OH 43614, USA

    8 shared publications
  • Beata Lecka-Czernik

    Department of Orthopaedic Surgery, University of Toledo Health Sciences Campus, Toledo, USA

    7 shared publications
  • Sonia M. Najjar

    Departments of Physiology and Pharmacology (L.A.S., M.W., T.D.H., S.S.K., L.R., S.M.N., B.L.-C., E.R.S.), University of Toledo College of Medicine and Life Sciences, Toledo, Ohio 43614-5804 3 The Center for Diabetes and Endocrine Research (L.A.S., M.W., T.D.H., S.K., L.R., S.M.N., B.L.-C., E.R.S.), University of Toledo College of Medicine and Life Sciences, Toledo, Ohio 43614-5804

    6 shared publications
  • Weinian Shou

    CHerman B. Wells Center for Pediatric Research (W.S.), Section of Pediatric Cardiology, Department of Pediatrics, Indiana University School of Medicine, Indianapolis, Indiana 46202

    4 shared publications
  • Harrison A. Cash

    3 shared publications

Latest Publications

  • Open Access

    Marrow Adipose Tissue: Skeletal Location, Sexual Dimorphism, and Response to Sex Steroid Deficiency

    by Beata Lecka-Czernik, Lance A. Stechschulte, Piotr J. Czernik, Shermel B. Sherman, Shilong Huang, Amrei Krings

    Marrow adipose tissue (MAT) is unique with respect to origin, metabolism, and function. MAT is characterized with high heterogeneity which correlates with skeletal location and bone metabolism. This fat depot is also highly sensitive to various hormonal, environmental, and pharmacologic cues to which it responds with changes in volume and/or metabolic phenotype. We have demonstrated previously that MAT has characteristics of both white (WAT) and brown (BAT)-like or beige adipose tissue, and that beige phenotype is attenuated with aging and in diabetes. Here, we extended our analysis by comparing MAT phenotype in different locations within a tibia bone of mature C57BL/6 mice and with respect to the presence of sex steroids in males and females. We report that MAT juxtaposed to trabecular bone of proximal tibia (pMAT) is characterized by elevated expression of beige fat markers including Ucp1, HoxC9, Prdm16, Tbx1 and Dio2, as compared to MAT located in distal tibia (dMAT). There is also a difference in tissue organization with adipocytes in proximal tibia being dispersed between trabeculae, while adipocytes in distal tibia being densely packed. Higher trabecular bone mass in males correlates with lower pMAT volume and higher expression of beige markers in the same location, as compared to females. However, there is no sexual divergence in the volume and transcriptional profile of dMAT. A removal of ovaries in females resulted in decreased cortical bone mass and increased volume of both pMAT and dMAT, as well as volume of gonadal WAT. Increase in pMAT volume was associated with marked increase in Fabp4 and Adiponectin expression and relative decrease in beige fat gene markers. A removal of testes in males resulted in cortical and trabecular bone loss and the tendency to increased volume of both pMAT and dMAT, despite a loss of gonadal WAT. Orchiectomy did not affect the expression of white and beige adipocyte gene markers. In conclusion, expression profile of beige adipocyte gene markers correlates with skeletal location of active bone remodeling and higher trabecular bone mass, however bone loss resulted from sex steroid deficiency is not proportional to MAT expansion at the same skeletal location.


  • Reciprocal Regulation of PPARγ and RUNX2 Activities in Marrow Mesenchymal Stem Cells: Fine Balance between p38 MAPK and Protein Phosphatase 5

    by Lance A. Stechschulte, Beata Lecka-Czernik

    Purpose of Review Post-translational modifications (PTMs), specifically serine phosphorylation, are essential for determination and tuning up an activity of many proteins, including those that are involved in the control of gene transcription. Transcription factors PPARγ2 and RUNX2 are essential for mesenchymal stem cell (MSC) commitment to either adipocyte or osteoblast lineage. This review is summarizing current knowledge how serine phosphorylation PTMs regulate activities of both transcription factors and MSCs lineage commitment. Recent Findings Both PPARγ2 and RUNX2 transcriptional activities are regulated by similar PTMs, however with an opposite outcome. The same p38 MAPK mediates serine phosphorylation that leads to activation of RUNX2 and inactivation of PPARγ2. The process of protein phosphorylation is balanced with a process of protein dephosphorylation. Protein phosphatase 5 simultaneously dephosphorylates both proteins, which results in activation of PPARγ2 and inactivation of RUNX2. Summary This review provides a summary of the “yin yang” fine-tuned mechanism by which p38 MAPK and PP5 regulate MSCs lineage commitment.


  • Open Access

    Glucocorticoid Receptor β Induces Hepatic Steatosis by Augmenting Inflammation and Inhibition of the Peroxisome Proliferator-activated Receptor (PPAR) α

    by Joseph S. Marino, Lance A. Stechschulte, David E. Stec, Andrea Nestor-Kalinoski, Sydni Coleman, Terry D. Hinds


  • FKBP51 Null Mice Are Resistant to Diet-Induced Obesity and the PPARγ Agonist Rosiglitazone

    by Lance A. Stechschulte, Bin Qiu, Manya Warrier, Terry D. Hinds, Man Zhang, Hao Gu, Yuxue Xu, Saja S. Khuder, Lucia Russo, Sonia M. Najjar, et al.

    FK506-binding protein-51 (FKBP51) is a molecular cochaperone recently shown to be a positive regulator of peroxisome proliferator-activated receptor (PPAR)γ, the master regulator of adipocyte differentiation and function. In cellular models of adipogenesis, loss of FKBP51 not only reduced PPARγ activity but also reduced lipid accumulation, suggesting that FKBP51 knock-out (KO) mice might have insufficient development of adipose tissue and lipid storage ability. This model was tested by examining wild-type (WT) and FKBP51-KO mice under regular and high-fat diet conditions. Under both diets, FKBP51-KO mice were resistant to weight gain, hepatic steatosis, and had greatly reduced white adipose tissue (WAT) but higher amounts of brown adipose tissue. Under high-fat diet, KO mice were highly resistant to adiposity and exhibited reduced plasma lipids and elevated glucose and insulin tolerance. Profiling of perigonadal and sc WAT revealed elevated expression of brown adipose tissue lineage genes in KO mice that correlated increased energy expenditure and a shift of substrate oxidation to carbohydrates, as measured by indirect calorimetry. To directly test PPARγ involvement, WT and KO mice were fed rosiglitazone agonist. In WT mice, rosiglitazone induced whole-body weight gain, increased WAT mass, a shift of substrate oxidation to lipids, and elevated expression of PPARγ-regulated lipogenic genes in WAT. In contrast, KO mice had reduced rosiglitazone responses for these parameters. Our results identify FKBP51 as an important regulator of PPARγ in WAT and as a potential new target in the treatment of obesity and diabetes.


  • Open Access

    PPARG Post-translational Modifications Regulate Bone Formation and Bone Resorption

    by L.A. Stechschulte, P.J. Czernik, Z.C. Rotter, F.N. Tausif, C.A. Corzo, D.P. Marciano, A. Asteian, J. Zheng, J.B. Bruning, T.M. Kamenecka, et al.


  • Open Access

    Analysis of FK506, timcodar (VX‐853) and FKBP51 and FKBP52 chaperones in control of glucocorticoid receptor activity and phosphorylation

    by Terry D. Hinds, Lance A. Stechschulte, Fadel Elkhairi, Edwin R. Sanchez

    The immunosuppressive ligandFK506 and theFK506‐binding proteinFKBP52 are stimulatory to glucocorticoid receptor (GR) activity. Here, we explore the underlying mechanism by comparingGRactivity and phosphorylation status in response toFK506 and the novel nonimmunosuppressive ligand timcodar (VX‐853) and in the presence and absence ofFKBP52 and the closely related proteinFKBP51. Using mouse embryonic fibroblast cells (MEFs) deficient knockout (KO) inFKBP51 orFKBP52, we show decreasedGRactivity at endogenous genes in 52KOcells, but increased activity in 51KOcells. In 52KOcells, elevated phosphorylation occurred at inhibitory serine 212 and decreased phosphorylation at the stimulatory S220 residue. In contrast, 51KOcells showed increasedGRphosphorylation at the stimulatory residues S220 and S234. In wild‐type (WT)MEFcells, timcodar, likeFK506, potentiated dexamethasone‐inducedGRtranscriptional activity at two endogenous genes. Using 52KOand 51KO MEFcells,FK506 potentiatedGRactivity in 51KOcells but could not do so in 52KOcells, suggestingFKBP52 as the major target ofFK506 action. LikeFK506, timcodar potentiatedGRin 51KOcells, but it also increasedGRactivity in 52KOcells. Knock‐down ofFKBP51 in the 52KOcells showed that the latter effect of timcodar requiredFKBP51. Thus, timcodar appears to have a dual specificity forFKBP51 andFKBP52. This work demonstrates phosphorylation as an important mechanism inFKBPcontrol ofGRand identifies the first nonimmunosuppressive macrolide capable of targetingGRaction.


  • Open Access

    FKBP51 Reciprocally Regulates GRα and PPARγ Activation via the Akt-p38 Pathway

    by Lance A. Stechschulte, Terry D. Hinds, Simona S. Ghanem, Weinian Shou, Sonia M. Najjar, Edwin R. Sanchez

    FK506-binding protein 51 (FKBP51) is a negative regulator of glucocorticoid receptor-α (GRα), although the mechanism is unknown. We show here that FKBP51 is also a chaperone to peroxisome proliferator–activated receptor-γ (PPARγ), which is essential for activity, and uncover the mechanism underlying this differential regulation. In COS-7 cells, FKBP51 overexpression reduced GRα activity at a glucocorticoid response element-luciferase reporter, while increasing PPARγ activity at a peroxisome proliferator response element reporter. Conversely, FKBP51-deficient (knockout) (51KO) mouse embryonic fibroblasts (MEFs) showed elevated GRα but reduced PPARγ activities compared with those in wild-type MEFs. Phosphorylation is known to exert a similar pattern of reciprocal modulation of GRα and PPARγ. Knockdown of FKBP51 in 3T3-L1 preadipocytes increased phosphorylation of PPARγ at serine 112, a phospho-residue that inhibits activity. In 51KO cells, elevated phosphorylation of GRα at serines 220 and 234, phospho-residues that promote activity, was observed. Because FKBP51 is an essential chaperone to the Akt-specific phosphatase PH domain leucine-rich repeat protein phosphatase, Akt signaling was investigated. Elevated Akt activation and increased activation of p38 kinase, a downstream target of Akt that phosphorylates GRα and PPARγ, were seen in 51KO MEFs, causing activation and inhibition, respectively. Inactivation of p38 with PD169316 reversed the effects of FKBP51 deficiency on GRα and PPARγ activities and reduced PPARγ phosphorylation. Last, loss of FKBP51 caused a shift of PPARγ from cytoplasm to nucleus, as previously shown for GRα. A model is proposed in which FKBP51 loss reciprocally regulates GRα and PPARγ via 2 complementary mechanisms: activation of Akt-p38–mediated phosphorylation and redistribution of the receptors to the nucleus for direct targeting by p38.